Cipla A.I CyberSecurity Scoring
01/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Cipla in 2026.
No incidents recorded for Cipla in 2026.
No incidents recorded for Cipla in 2026.
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Latest updates, reports, and threat intel affecting the global network.
TAC InfoSec share price hit a new high of Rs 1112.45, locked in an upper circuit for the 9th straight day, and surged 46 per cent during the...
Mankind Pharma: The company launched its qualified institutional placement (QIP) at a floor price of Rs 2616.55 per share aiming to raise up...
Cipla, one of India's leading pharmaceutical companies, has reportedly been targeted by the Akira ransomware group in a cyberattack that allegedly resulted in...
Cipla ended the previous trading day at Rs 1406.7, marking a 3-month return of 2.88%. The pharmaceutical company's stock has shown steady...
The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) for a site transfer...
Co-working giant WeWork is striving to gain a foothold in big Indian cities. Business Standard's Surajeet Das Gupta caught up with Karan...
Cipla Ltd has asked its information technology team to be “paranoid" about its cybersecurity following attacks on two large pharmaceutical firms.
Cipla CFO Kedar Upadhye has asked his IT team to be as paranoid as possible and take the help of experts, and continue to track some hostile...
We had four aspects of the business to consider — manufacturing, R&D, corporate offices and sales & marketing. Each presented its own set of...
MojoX::Authentication versions before 0.006 for Perl allow SAML authentication bypass because parse_assertion builds Net::SAML2::Binding::POST without a trust anchor. parse_assertion in MojoX::Authentication::Model::SAML2 calls Net::SAML2::Binding::POST->new with no cacert, cert_text or anchors argument, then passes the returned XML to Net::SAML2::Protocol::Assertion->new_from_xml with the IdP signing certificate as cacert. In Net::SAML2 before 0.86 that certificate guards only encrypted assertions, so the signature on an unencrypted assertion is checked against the certificate the response itself carries. An attacker starts a SAML login, then posts a response signed with a certificate of their own. The audience, InResponseTo and timestamp checks that follow are all satisfiable by the attacker, so the response authenticates any NameID it carries.
A weakness has been identified in itsourcecode Sales and Inventory System 1.0. Affected by this vulnerability is an unknown functionality of the file /pages/sup_del.php?type=supplier. Executing a manipulation of the argument ID can lead to sql injection. The attack may be performed from remote. The exploit has been made available to the public and could be used for attacks.
A security flaw has been discovered in mwiede jsch up to 2.28.5. Affected is the function getRevokedKeys of the file src/main/java/com/jcraft/jsch/KnownHosts.java. Performing a manipulation of the argument known_hosts results in improper check for certificate revocation. The attack is possible to be carried out remotely. The attack is considered to have high complexity. The exploitability is told to be difficult. The exploit has been released to the public and may be used for attacks. Upgrading to version 2.28.6 is able to address this issue. The patch is named 194a2f76a5c0f1c3f778565be3fd66bcafc42d23. You should upgrade the affected component.
A security vulnerability has been detected in JeecgBoot up to 3.9.3. This vulnerability affects the function exportXls of the file jeecg-boot/jeecg-boot-module/jeecg-boot-module-airag/src/main/java/org/jeecg/modules/airag/llm/controller/AiragModelController.java. Such manipulation of the argument credential leads to improper access controls. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 3.9.5 is able to resolve this issue. The name of the patch is a2be896f753936956ee6863b632b8e5a0231345c. You should upgrade the affected component.
A weakness has been identified in valkey-io valkey up to 9.0.5/9.1.1. This affects the function kvstoreGetHashtable of the file src/kvstore.c. This manipulation of the argument didx causes out-of-bounds read. It is possible to initiate the attack remotely. The attack is considered to have high complexity. It is indicated that the exploitability is difficult. The exploit has been made available to the public and could be used for attacks. Patch name: 4691888e7fab3df128f0bde5750c9fde2ae552fa. To fix this issue, it is recommended to deploy a patch. Exploitation requires cluster mode plus attacker-controlled dump.rdb at startup (data-dir write access, replication feed, or a stored crafted RDB) - an attacker-position DoS at boot, not network pre-auth. The issue report was closed stating it "is worth fixing for the sake of memory safety… but I don't think it meets our bar for a security disclosure."
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.